1. Home
  2. SGA vs BOLD Comparison

SGA vs BOLD Comparison

Compare SGA & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Saga Communications Inc. (FL)

SGA

Saga Communications Inc. (FL)

HOLD

Current Price

$9.11

Market Cap

61.3M

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$2.51

Market Cap

57.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SGA
BOLD
Founded
1986
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
61.3M
57.5M
IPO Year
1994
2024

Fundamental Metrics

Financial Performance
Metric
SGA
BOLD
Price
$9.11
$2.51
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
20.5K
2.3M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
9.05%
N/A
EPS Growth
N/A
32.47
EPS
N/A
N/A
Revenue
$124,829,000.00
N/A
Revenue This Year
$6.74
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.65
N/A
52 Week Low
$8.24
$0.96
52 Week High
$13.81
$2.79

Technical Indicators

Market Signals
Indicator
SGA
BOLD
Relative Strength Index (RSI) 52.95 76.94
Support Level $8.24 $1.08
Resistance Level $9.46 $2.79
Average True Range (ATR) 0.33 0.14
MACD 0.13 0.08
Stochastic Oscillator 83.64 79.21

Price Performance

Historical Comparison
SGA
BOLD

About SGA Saga Communications Inc. (FL)

Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: